SIMULATIONS PLUS INVESTIGATION: Bragar Eagel & Squire, P.C. - GlobeNewswire14 hours ago • Google News
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy - Nature2 weeks ago • Google News
Does Simulations Plus (SLP) Have the Potential to Rally 25.61% as Wall Street Analysts Expect? - Yahoo Finance3 days ago • Google News